Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.64), $0.14 better than the analyst estimate of ($0.78).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• DA Davidson Reiterates Buy Rating on Vulcan Materials Company (VMC)
• Raymond James Reiterates Underperform Rating on Lennar (LEN)